Risankizumab
Indication
Treating moderately to severely active ulcerative colitis (NICE TA998)
NICE TA998 - Risankizumab for treating moderately to severely active ulcerative colitis
Red
Brand:
Nice TA:
998
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
1.1 Risankizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if:
- a tumour necrosis factor (TNF)-alpha inhibitor:
- has not worked (that is the condition has not responded well enough or has lost response to treatment), or
- cannot be tolerated or is not suitable, and
- the company provides it according to the commercial arrangement.